Table 4.
Characteristics | HPAF (n=18) |
HP without AF (n=102) |
p-value |
---|---|---|---|
Autoimmune serologic tests | |||
ANA ≥ 1:320, n (%) | 11 (61.1) | 23 (22.5) | 0.001 |
RF ≥ 3x upper limit normal, n (%) | 0 (0) | 1 (1.0) | 1.000 |
Anti-ENA RNP, n (%) | 1 (5.5) | 0 (0) | 0.154 |
Anti-topoisomerase (Scl-70), n (%) | 1 (5.5) | 1 (1.0) | 0.285 |
Anti-Ro (SS-A), n (%) | 2 (11.1) | 0 (0) | 0.023 |
Anti-La (SS-B), n (%) | 0 (0) | 1 (1.0) | 1.000 |
Anti-dsDNA, n (%) | 3 (16.7) | 1 (1.0) | 0.011 |
Anti-CCP, n (%) | 2 (11.1) | 1 (1.0) | 0.061 |
C-reactive protein‘, mean (±SD) | 13.6 (26.2) | 9.9 (25.6) | 0.575 |
Autoimmune clinical features | |||
Raynaud’s phenomenon, n (%) | 3 (16.7) | 6 (5.9) | 0.109 |
Arthralgias/multiple joint swelling, n (%) | 6 (33.3) | 3 (2.9) | <0.001 |
Morning stiffness, n (%) | 6 (33.3) | 3 (2.9) | <0.001 |
Dry mouth/dry eyes, n (%) | 12 (66.7) | 23 (22.5) | <0.001 |
Proximal muscle weakness, n (%) | 2 (11.1) | 2 (2.0) | 0.106 |
HP = Hypersensitivity Pneumonitis; HPAF= Hypersensitivity Pneumonitis with Autoimmune features as defined in the text; AF = Autoimmune features